JM
Publicaties op Oncologisch.com
Final totale overleving and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of an...
Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin 2 in gevorderd c...
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen depriv...
OS van tebentafusp versus nivolumab-ipilimumab bij eerstelijns uveamelanoom